middl
east
respiratori
syndrom
coronaviru
newli
emerg
viru
caus
sever
respiratori
diseas
august
laboratori
confirm
case
fatal
cfr
report
world
health
mer
case
identifi
countri
middl
east
north
africa
europ
us
asia
new
mer
case
continu
detect
cdc
continu
surveil
mer
case
outbreak
unit
state
current
diagnost
algorithm
identif
serum
antibodi
patient
suspect
histori
infect
includ
initi
screen
indirect
elisa
use
nucleocapsid
n
protein
confirm
immunofluoresc
stain
cell
microneutr
titrat
mnt
intern
group
primarili
use
combin
indirect
elisa
spike
protein
confirmatori
neutral
elisa
found
correl
well
neutral
spike
protein
target
neutral
antibodi
includ
diagnost
algorithm
current
studi
report
valid
indirect
elisa
use
combin
n
elisa
mnt
identif
specif
serum
antibodi
patient
histori
infect
collect
neg
normal
human
sera
n
obtain
throh
contract
cdc
emori
univers
transfus
servic
ethic
approv
sampl
collect
use
approv
cdc
protocol
number
emori
univers
protocol
number
institut
review
board
donor
ident
held
emori
univers
transfus
servic
releas
cdc
accord
institut
approv
irb
protocol
sampl
use
studi
analyz
anonym
serum
confirm
patient
use
posit
control
assay
posit
control
serum
collect
first
import
case
unit
state
case
investig
neutral
reciproc
endpoint
titer
panel
nine
serum
patient
neutral
antibodi
collect
outbreak
investig
investig
outbreak
specimen
prepar
jordan
central
public
health
laboratori
amman
jordan
ship
cdc
test
person
identifi
held
cdc
cdc
irb
deem
use
sera
subject
research
research
determin
human
serum
high
titer
human
coronavirus
collect
coronaviru
investig
examin
assay
cross
reactiv
person
identifi
head
sampl
therefor
cdc
irb
deem
use
sera
subject
research
research
determin
laboratori
confirm
patient
serum
also
includ
neg
control
recombin
spike
protein
purchas
sino
biolog
beij
china
catalog
number
manufactur
describ
protein
ectodomain
includ
amino
acid
strain
produc
baculoviru
immulon
microtit
plate
thermo
scientif
rochest
ny
coat
overnight
wash
three
time
block
surmod
eden
prairi
mn
h
block
plate
incub
serum
dilut
prepar
milk
h
wash
three
time
incub
goat
igg
h
l
kpl
gaithersburg
md
x
wash
incub
peroxidas
substrat
kpl
gaithersburg
md
min
reaction
termin
ad
peroxidas
stop
solut
sodium
dodecyl
sulfat
absorb
measur
nm
use
tecan
infin
micropl
reader
mannedof
switzerland
absorb
optic
densiti
valu
neg
control
well
n
coat
pb
subtract
divid
od
valu
well
p
averag
od
valu
well
calcul
ratio
pn
recombin
produc
cell
describ
elisa
also
perform
previous
western
blot
analysi
purifi
n
pet
control
lysat
purifi
run
sd
page
transfer
pvdf
membran
sera
without
reactiv
nh
sar
dilut
use
probe
blot
hrp
goat
anti
human
iga
igg
igm
h
l
blot
develop
dab
characterist
roc
analysi
use
determin
diagnost
sensit
specif
optim
test
od
valu
assay
use
excel
ibm
spss
statist
briefli
diagnost
sensit
se
specif
sp
elisa
test
result
calcul
use
microneutr
result
refer
gold
standard
test
posit
neg
sampl
optim
test
od
valu
ascertain
plot
sensit
se
specif
sp
elisa
od
valu
two
plot
intersect
two
curv
determin
od
elisa
use
commerci
prepar
purifi
ectodomain
optim
coat
block
condit
indirect
elisa
use
known
neg
posit
human
sera
data
shown
optim
test
sera
normal
human
donor
one
serum
confirm
patient
cross
reactiv
reactiv
indirect
elisa
dilut
normal
human
sera
od
valu
less
figur
remain
three
normal
sera
od
valu
posit
control
serum
od
valu
figur
use
od
cutoff
one
normal
human
sera
cutoff
order
precis
test
specif
sensit
elisa
nine
true
neg
sera
reciproc
endpoint
microneutr
titer
less
nine
true
posit
sera
reciproc
endpoint
microneutr
titer
rang
test
dilut
figur
roc
analysi
perform
calcul
diagnost
sensit
true
posit
specif
true
neg
assay
standard
screen
dilut
sensit
elisa
remain
greater
od
figur
specif
increas
od
figur
serum
dilut
elisa
remain
highli
specif
lose
sensit
higher
od
expect
figur
sake
comparison
roc
analysi
n
elisa
shown
true
posit
true
neg
sera
screen
dilut
figur
sensit
n
elisa
high
across
wide
rang
od
specif
increas
od
cross
reactiv
sera
patient
known
histori
human
coronaviru
infect
test
elisa
western
blot
analysi
figur
plate
coat
recombin
human
sera
dilut
use
elisa
littl
cross
reactiv
detect
pool
sera
patient
histori
human
coronaviru
infect
pool
normal
human
serum
nh
even
dilut
figur
observ
cross
reactiv
human
serum
dilut
though
od
cutoff
valu
figur
serum
control
serum
final
reciproc
endpoint
titer
consist
high
neutral
antibodi
titer
detect
microneutr
assay
figur
sera
human
histori
coronaviru
infect
normal
human
sera
reciproc
endpoint
titer
less
consid
posit
set
sera
also
test
western
blot
analysi
purifi
recombin
n
protein
kda
neg
control
lysat
pet
control
purifi
ectodomain
protein
kda
run
gel
transfer
membran
sera
patient
faintli
detect
n
protein
figur
sera
patient
also
faintli
detect
protein
cross
reactiv
seen
sar
serum
protein
figur
serum
patient
strongli
detect
n
expect
result
suggest
weak
cross
reactiv
n
protein
sera
patient
histori
coronaviru
infect
cross
reactiv
strong
enough
result
posit
signal
elisa
studi
suggest
may
cross
reactiv
sar
patient
sera
studi
limit
avail
one
patient
studi
valid
elisa
use
recombin
ectodomain
opt
retain
n
elisa
serolog
screen
process
believ
n
elisa
complementari
sever
reason
first
demonstr
roc
analysi
n
lower
od
elisa
specif
n
elisa
retain
higher
sensit
across
larg
rang
od
data
consist
one
public
examin
serial
blood
draw
singl
patient
suggest
elisa
sensit
n
observ
signific
differ
qualiti
quantiti
polyclon
antibodi
respons
conflict
data
may
simpli
explain
human
variat
immun
respons
recent
work
examin
panel
patient
serum
suggest
elisa
sensit
increas
lower
breakpoint
would
captur
larger
percentag
patient
seroconvert
seen
sever
patient
never
develop
detect
antibodi
develop
n
antibodi
data
shown
second
reason
retain
n
elisa
evid
antibodi
coronaviru
n
protein
detect
earlier
infect
protein
specif
infect
studi
indic
antibodi
n
protein
appear
antibodi
frequent
receiv
serum
patient
acut
ill
suspect
infect
part
surveil
unit
state
need
detect
earli
possibl
infect
third
n
elisa
may
sensit
examin
n
cross
reactiv
suggest
antibodi
direct
n
may
cross
react
therefor
use
n
elisa
may
captur
sensit
specif
inform
part
screen
process
aim
captur
mani
potenti
posit
serum
possibl
perform
confirmatori
assay
summari
new
test
algorithm
n
elisa
use
screen
assay
sera
dilut
sera
od
assay
cutoff
dilut
serial
fourfold
use
endpoint
titer
determin
sera
posit
either
n
n
titer
test
via
microneutr
live
along
neg
sera
defin
posit
serolog
posit
two
three
assay
test
n
elisa
elisa
microneutr
posit
microneutr
alon
microneutr
activ
confirm
posit
find
conclus
report
author
necessarili
repres
view
center
diseas
control
preventionth
nation
center
immun
respiratori
diseas
